Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Operating Expenses (2017 - 2025)

Autolus Therapeutics' Operating Expenses history spans 6 years, with the latest figure at $96.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 27.49% year-over-year to $96.8 million; the TTM value through Dec 2025 reached $345.9 million, up 37.52%, while the annual FY2025 figure was $345.9 million, 37.52% up from the prior year.
  • Operating Expenses reached $96.8 million in Q4 2025 per AUTL's latest filing, up from $92.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $96.8 million in Q4 2025 to a low of $15.0 million in Q4 2022.
  • Average Operating Expenses over 4 years is $56.5 million, with a median of $51.1 million recorded in 2023.
  • The largest YoY upside for Operating Expenses was 256.09% in 2023 against a maximum downside of 0.88% in 2023.
  • A 4-year view of Operating Expenses shows it stood at $15.0 million in 2022, then soared by 256.09% to $53.3 million in 2023, then soared by 42.47% to $75.9 million in 2024, then rose by 27.49% to $96.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Operating Expenses are $96.8 million (Q4 2025), $92.8 million (Q3 2025), and $82.1 million (Q2 2025).